Published on 24 Feb 2022 on Zacks via Yahoo Finance
MacroGenics (MGNX) Reports Q4 Loss, Misses Revenue Estimates
MacroGenics (MGNX) came out with a quarterly loss of $0.95 per share versus the Zacks Consensus Estimate of a loss of $0.83. This compares to earnings of $0.02 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of -14.46%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.63 per share when it actually produced a loss of $0.86, delivering a surprise of -36.51%.
Over the last four quarters, the company has not been able to surpass consensus EPS estimates.